These calls will support ambitious, collaborative projects that tackle Europe’s most pressing health challenges. With a wide range of topics across key Destinations, there’s a wealth of opportunities for researchers, innovators, and stakeholders across the health ecosystem. Whether your work addresses prevention, diagnosis, treatment, or healthcare delivery, there’s a Horizon Europe opportunity for you.
Explore the Full List of Cluster 1 – Health Topics:
- Staying healthy in a rapidly changing society
- Living and working in a health-promoting environment
- Tackling diseases and reducing disease burden
- Developing and using new tools, technologies and digital solutions for a healthy society
- Maintaining an innovative, sustainable, and competitive EU health industry
- Ensuring equal access to innovative, sustainable, and high-quality healthcare
These topics reflect Europe’s commitment to a more resilient, equitable, and digitally empowered healthcare system.
Next Calls
| Topics | Type | Budget (EUR million) | Budget/project | Projects expected to be funded | Deadline |
|---|---|---|---|---|---|
Destination – Staying healthy in a rapidly changing society |
|||||
| HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion | RIA | 39.30 | 6.00 to 8.00 | 5 |
17 Feb 2027 |
Destination – Living and working in a health-promoting environment |
|||||
| HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change | RIA | 45.00 | 10.00 to 11.00 | 4 | 17 Feb 2027 |
| HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change | PCP | 20.0046 | 4.00 to 5.00 | 4 | 17 Feb 2027 |
Destination – Tackling diseases and reducing disease burden |
|||||
| HORIZON-HLTH-2026-03-DISEASE-13: European Partnership for Pandemic Preparedness (Phase 2) | COFUND | 30.00 | Around 63.00 | 1 | 13 Apr 2027 |
| HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential | RIA | 44.20 | 9.00 to 11.00 | 5 | 17 Feb 2027 |
| HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses | RIA | 37.30 | 9.00 to 10.00 | 4 | 17 Feb 2027 |
| HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses | RIA | 37.30 | 9.00 to 10.00 | 4 | 17 Feb 2027 |
| HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials | RIA | 44.20 | 8.00 to 10.00 | 5 | 17 Feb 2027 |
| HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic noncommunicable diseases in children and young people (GACD) | RIA | 11.80 | 3.00 to 4.00 | 3 | 17 Feb 2027 |
| HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases | RIA | 63.80 | 7.00 to 8.00 | 8 | 17 Feb 2027 (First Stage), 16 Sep 2027 (Second Stage) |
| HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for non-communicable diseases | RIA | 39.30 | Around 10.00 | 4 | 17 Feb 2027 (First Stage), 16 Sep 2027 (Second Stage) |
Destination – Ensuring equal access to innovative, sustainable, and high-quality healthcare |
|||||
| HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications | RIA | 38.00 | 8.00 to 10.00 | 4 | 17 Feb 2027 |
Destination – Developing and using new tools, technologies and digital solutions for a healthy society |
|||||
| HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic noncommunicable diseases | RIA | 44.20 | 6.00 to 8.00 | 6 | 17 Feb 2027 (First Stage), 16 Sep 2027 (Second Stage) |
| HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine | RIA | 39.30 | 7.00 to 10.00 | 4 | 16 Sep 2027 |
| HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis | RIA | 39.30 | 10.00 to 12.00 | 4 | 16 Sep 2027 |
| HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare | CSA | 2.90 | Around 2.90 | 1 | 16 Sep 2027 |
Destination – Maintaining an innovative, sustainable, and competitive EU health industry |
|||||
| HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals | RIA | 24.50 | 6.00 to 8.00 | 4 | 17 Feb 2027 |
| HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics | IA | 39.30 | 5.00 to 7.00 | 6 | 17 Feb 2027 (First Stage), 16 Sep 2027 (Second Stage) |
